A large genetic study suggests that Alzheimer’s disease and Parkinson’s disease are linked to the body’s metabolism in strikingly different ways. That may help explain why metabolic treatments, including GLP-1-based drugs, do not necessarily have the same effects across neurodegenerative diseases.
